中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2012年
38期
48-49
,共2页
慢性乙型肝炎%拉米夫定%阿德福韦酯
慢性乙型肝炎%拉米伕定%阿德福韋酯
만성을형간염%랍미부정%아덕복위지
chronic hepatitis B%lamivudine adefovir dipivoxil
目的探讨拉米夫定联合阿德福韦酯治疗慢性乙型肝炎的临床疗效.方法将60例慢性乙型肝炎患者随机分为观察组和对照组各30例,观察组采用拉米夫定联合阿德福韦酯治疗,对照组单纯用拉米夫定治疗.比较分析两组的临床治疗效果.结果治疗3、6个月时观察组ALT复常率及HBV-DNA阴转率均显著高于对照组(P<0.05),12个月时两组差异不具有统计学意义(P>0.05);两组HBeAg阴转率在治疗3、6个月时差异不显著(P>0.05),在12个月时观察组显著高于对照组(P<0.05);观察组耐药发生率显著低于对照组(P<0.05);两组不良反应差异不显著(P>0.05).结论拉米夫定联合阿德福韦酯治疗慢性乙型肝炎疗效好,耐药性发生率低,且无严重不良反应,值得进行临床推广.
目的探討拉米伕定聯閤阿德福韋酯治療慢性乙型肝炎的臨床療效.方法將60例慢性乙型肝炎患者隨機分為觀察組和對照組各30例,觀察組採用拉米伕定聯閤阿德福韋酯治療,對照組單純用拉米伕定治療.比較分析兩組的臨床治療效果.結果治療3、6箇月時觀察組ALT複常率及HBV-DNA陰轉率均顯著高于對照組(P<0.05),12箇月時兩組差異不具有統計學意義(P>0.05);兩組HBeAg陰轉率在治療3、6箇月時差異不顯著(P>0.05),在12箇月時觀察組顯著高于對照組(P<0.05);觀察組耐藥髮生率顯著低于對照組(P<0.05);兩組不良反應差異不顯著(P>0.05).結論拉米伕定聯閤阿德福韋酯治療慢性乙型肝炎療效好,耐藥性髮生率低,且無嚴重不良反應,值得進行臨床推廣.
목적탐토랍미부정연합아덕복위지치료만성을형간염적림상료효.방법장60례만성을형간염환자수궤분위관찰조화대조조각30례,관찰조채용랍미부정연합아덕복위지치료,대조조단순용랍미부정치료.비교분석량조적림상치료효과.결과치료3、6개월시관찰조ALT복상솔급HBV-DNA음전솔균현저고우대조조(P<0.05),12개월시량조차이불구유통계학의의(P>0.05);량조HBeAg음전솔재치료3、6개월시차이불현저(P>0.05),재12개월시관찰조현저고우대조조(P<0.05);관찰조내약발생솔현저저우대조조(P<0.05);량조불량반응차이불현저(P>0.05).결론랍미부정연합아덕복위지치료만성을형간염료효호,내약성발생솔저,차무엄중불량반응,치득진행림상추엄.
Objective: To investigate efficacy of lamivudine combined with adefovir dipivoxil in the treatment of chronic hepatitis B. Methods: 60 cases of chronic hepatitis B were randomly divided into observation group and control group 30 cases , the observation group were lamivudine combined with adefovir dipivoxil treatment and control group were treated with lamivudine treatment . Compared the clinical efficacy of the two groups .Results: Treatment of 3 and 6 months observation group of ALT often rate and HBV-DNA negative conversion rate was significantly higher than the control group ( P <0.05 ), at 12 months , the difference was not statistically significant ( P > 0.05 ) ; the the two groups of HBeAg negative conversion rate in the the 3,6 months of treatment , the difference was not significantly ( P > 0.05 ) , and group was significantly higher than that in the control group ( P <0.05 ) observation in the 12 month ; the drug-resistant the incidence of of the observation group significantly lower than the control group ( P <0.05 ) ; two adverse reactions was no significant difference ( P > 0.05 ).Conclusion: Lamivudine combined with adefovir dipivoxil for chronic hepatitis B is effective and have low resistance, no serious adverse reactions.